Member Info for chester18

Hi krafty1305

Excellent news today and as you say putting Modi1 aside, I feel the next big Scancell news will be about the GenMab deal.

GenMab signed that deal just over 9 months ago ( 25th October 2022 ). LD said in the, Proactive Investors in person interview, that GenMab were reported to be very happy with our Antibody Target and Scancell were excited about the prospects of that deal proceeding towards the next milestone ( or words to that effect ).

I am still hoping that we will also receive a more comprehensive Modi1 progress report during August with numbers of patients dosed, a table of results from scans, how many patients have completed 1st stage treatment ( 5 doses ) and the outcomes seen at 24 weeks Scans. Similar to the RNS on Feb 21st at 8 weeks Scans.

Chester.

Hi C11

I realise you can read my post as overly negative on the chances of our success, but I was putting forward my frustration about the timing and the random coverage of that July 10th RNS.

We were all waiting for the next significant data read out from ModiFy. I don't think anyone would have been surprised if there was no mention of the SCOPE trial because it had become just a background story, for now.

The information contained in the RNS was luke warm on ModiTope, big on Scib1 plus CPI, but that was going to be delayed so we can ( very rightly ) upgrade to iSCIB+.

The 6 month evaluation of our GlyMab products is great news but 6 months away and only a maybe.

In the current financial battle with inflation and interest rates we definitely did not need to present our cash flow as anything other than, we have cash for over a year and are in talks with several companies to do deals.

Many of us that have been around a while have supported the company in their past fund raisings. We are not Redmile who are collecting interest payments every month on their CLN's.

The big investor that is feeling our pain is Vulpes who invested £m's before Redmile arrived and they will be reeling at the current sub 10p shareprice.

Just my opinion as explained to Dracula1 why I am frustrated with the lack of shareholder consideration in the pitch and tone of that RNS.

I do think that we are now back to Radio Silence until September, I do hope I am wrong though.

We will have to wait and see.

Chester.

Hi Dracula1

It's so difficult to simply accept the retrace when we know there are so many positives to Scancells science and the platforms that have sprung from it.

My honest opinion is that Moditope will make a difference over the coming years, especially in conjuction with CPI's.

SCIB1 is looking very favourable but the change to iSCIB1+ means waiting another 6 to 12 months for that data.

My short term hopes are now pinned on either AvidiMab or the GlyMabs platforms being taken up in more than one of our collaborations. That would boost our bank account, allow the ModiFY and Scope trials to reach valuable trial points and raise the markets sentiment on the success of Scancell back to very positive.

Chester.

Hiya Dracula1

The trading is wafer thin. There are very approximately 450,000,000 shares in private hands and we are seeing what the market makers can do with a fragment of those shares.

The MM's make a market by stiring up the pot.

4% drops on a few thousand pounds worth of trades.

Until Scancell announce positive commercial news, that is, either a partnership with a large pharma on one of our platforms or a signed deal that brings in the right level of £m's, there will not be a sharp rise in the SP.

The last RNS poured cold water on any hopes of near term Positive Trial News and also snubbed out any remaining feeling that a cash generating deal was close to happening.

Under these circumstances and with in the current financial squeeze it's going to be near impossible for the SP to recover on sentiment alone.

I'm holding tight to my core investment as I do believe the news that will turn the tide is only a matter of time.

The issue now affecting the share price is how much time do we have to endure ?

Chester.

I'm still puzzling the reason for that update and the range of information contained, plus what was omitted.

The only thing that makes any sense is that it cleared the threshold for the Poster / Presentation submission for September's Conference. That closing submission date was 20th July.

Although it did also leave me with a feeling of 'this is all we want to share until after the September release'. I don't know why I felt that we were going back on Radio Silence but it is probably a combination of the RNS and video Interview that set that tone.

Therefore, for me, it wasn't to reassure the market, it wasn't to allow for Options and it wasn't to boost the companies profile.

I still hope that I am wrong and a full and complete ModiFY update will happen by the 21st August as it will be 6 months since the last report ( 21st February).

After all said we were promised regular updates from that study.

Chester.

Hope so bobbust, we need positive news asap.

This is SP decline is not something I really anticipated but it looks like last weeks 'Update' added to current market jitters has dropped us into the perfect storm.

Last weeks update of trial information was not to allow the purchase of LD's share options but to have market information in the open so we can do a Poster / Presentation at the conference in September. If that is true where have all the 250k share sells come from. Could it be our past director dealing with his July 31st share options ?

Whatever it is, it's another kick in the pants for loyal shareholders who have had to deal with many false horizons.

Chester.

If we do 'go it alone' and we need another £40m where would that level of investment come from ?

Let's presume that the data evidence is compelling but the large pharma companies want to stifel our future potential by offering low ball figures. Lindy will not sell out for a fraction of what a fully proven Ph3 Moditope could be worth.

Redmile could find another chunk of cash but that would cause issues about owning 80% of the company. There are ways it could be done but a simpler solution would be to bring on board a new Institutional investor. That would mean the CLN's owed to Redmile in 2025 no longer mean they would pass 50% of the shares issue. Lindy can proceed through the clinic bringing about a Trial with Modi2, then another Trial with the TCB Antibody she loves.

ISCIB+ would be close to registration.

You can clearly see the pathway that ends up with Scancell becoming the UKs version of BionTech.

Is this what we are seeing, the early stages of that strategy?

Chester .

Looking at the timeline of past events and RNS'es I theorised that August would be the month to announce the updated Data from the ModiFY Trial. The SCOPE trial was so veiled in secrecy that I had no idea when or what we would hear.

As many have said, Monday's RNS left many questions unanswered but does leave you feeling the message was :

"That's all for now folks"

"Next Update sometime in September"

"Have a Nice Day"

It was not what was needed and definitely not what was anticipated.

Chester.

Plus it's all Berms fault ..... 😁😁

So now we know it was not Lindy selling those shares, here's a good question :

If Mondays RNS was not clearing the ground for reasons of Insider Trading to allow LD to collect those options, what was it for ??

It didn't fully inform about the whole range of platforms just a mixed bag of 'where we are at'.

I can't figure out what would motivated such a 'half the story' RNS.

Perplexed....

Chester.

Hi violindog

I noticed that we were missing comments on TNBC. We know that late stage tumours are extremely hard to overpower no matter what is attempted. I would hope that Scancell are trying to figure out how to mount such a large attack of CD4 Killer 'T' Cells that these tumours can be undermined and eventually overcome.

As reported ModiTope is creating and then engaging with the targeted tumours but it would seem that the inflicted damage is not at present, sufficient enough to overwhelm the cancers ability to create new cells.

What the ModiFY Basket Trial is all about is to find those sweet spots either by number of doses, strength of those doses or in combination with other treatments.

At this very early stage against these hard to treat and aggressive tumours Scancell are having a measure of success. As the trial progresses Lindy and Co will learn where the improvements need to be.

As has been pointed out on this board, adoption of ModiTope in patients at a much earlier stage will be the key to overwhelming the targeted solid cancer.

IMO this recent update shows that Scancell are defintely heading in the right direction.

Chester.

WTP regarding your question of who it may be ....

"....The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company."

Who could this be? Is 6 months typically long enough to make an appraisal/bid?

Posted back in Feb this year :

We have four GlyMab collaborations. I presume the GenMab one was the first back in September 2019.

The second announced on the 16th December 2019 was with a Chinese BioTech.

The third 20th January 2020 with a US Based Clinical Stage Antibody company.

Then the pandemic shut everything down for a year at least.

The fourth and most recent 17th March 2022 with a Major European Pharma.

Taking the pandemic out of the timeline and presuming that GenMab were the first means the period from agreeing the collaboration to signing a commercial deal took approx two years.

Therefore the Chinese and US collaborations (if successful) cannot be very far from a decision. The fourth on this basis is at least a year away from being meaningful.

The point is that another one or two GlyMab deals could be very close.

Chester.

BionTech were and are very interested in our ModiTope enhanced 'T' Cells.

If that therapy works it will be BionTech's key to a personalised cancer treatment.

mRNa is still in its infancy and its success or failure is not assured.

Chester.

I totally agree CW, there are so many News worthy items that Scancell could share at any moment to extinguish the current vacuum.

For instance :

SCIB1/ iSCIB+

New Glycan or AvidiMab Deals / collaborations

Progress with the GenMab deal

TCB Antibody progress

MODI2 Progress towards the Clinic 2024.

Any Interest in Covidity ?

Plus the obvious, ModiFY Trial update.

Let's not forget 'Left Field', an absolute favourite tactic employed by Scancell on many occasions in the past.

Being able to compile such a news worthy list and not hearing from the company on any Trial or Deal or Laboratory progress for 4.1/2 months does focus our attention on, why ? ( in a good way ).

Chester.

The Trisha story was unique as her experience was fairly instant when you consider the percentage tumour regression after only 8 weeks. After those early revelations, news about 'trial outcomes' did cease until her story was in the Liverpool Echo.

To me it suggests that patients have been quietly and politely asked to keep any trial outcomes as close as possible.

IMO until we reach a point where 60 or 80 ish have all had the ModiFY full doses and have received all 5 of those doses, we really could not say with any confidence that ModiTope worked well for the majority of patients.

Scancells silence is a vacuum for our imaginations but the next ModiFY Data Readout should answer a lot of the current questions raised on this board.

Chester.

Hi WTP

The next data readout from Scancell will IMO give huge clues to our future potential.

As an investor I now understand that we are taking about a new treatment that will take time to penetrate these well established tumours.

In the poorly patients that have made it onto the ModiFY trial, partial or stable disease results will be amazing. Large bulky tumours and a low immune system leaves these patients with no current options.

If ModiTope is capable of giving these patients another 2 to 5 years of active life it will be hailed as a breakthrough. In combination with CPI's if the number of these patients who gain 5 years plus, rises by 20% or 30% it will be hailed as a blockbuster. Plus all the patents for CPI's can be reset to zero years, that itself will push up our value.

These are exciting times to be a holder of Scancell shares, we just have to keep our nerve and wait for Lindy to start shouting of the rooftop......🤞🤞

Chester.

Those epic deals in the £B's are always due to the perceived huge commercial potential.

We won't know the potential of Scancells ModiFY until the data readout on Cohort 4 plus CPi.

If the increase in the survival percentage numbers are significantly improved then the chances of a deal in the £B's would be very possible.

That data is probably 12 months away.

Chester.

Hi Berm,

It does show that Lindy knows the difference between running a commercial operation and running a purely scientific adventure. Something she has been accused of on here is putting the science project before the interests of her investors. Well in her own words it completely dispels that myth.

Chester.

I've read everything posted here over the last 2/3 days and appreciate that the reduction in the shareprice is a cause of concern. I also understand that under the current circumstances of interest rate increases combined with inflation means owning shares in a non profit making company is a luxury to far for many investors.

What is true is that the trials are proceeding without any hiccups, we know some patients have had positive results, I'm including Stabilisation of their disease as a positive outcome.

The ModiFY trial has moved safely and swiftly to Cohort 4, allowing the trial to expand towards the maximum intended target of 168 patients.

So clinically all looks well and we can be cautiously optimistic that the next data read out will be beyond encouraging.

Not withstanding the fact that NDA's could be in place which may hold up any planned RNS's, we should see that ModiFY Data by 21st August, it being a full 6 months since the last time we were told anything.

On the potential deals front it's anyone's guess.

We have many 'shots on goal', GenMab, GlyCans, AvidiMab, Covidity, SCIB1 and Moditope.

Let's hope one of those gets over the line soon.

Chester.

WETOOKPELHAM, your observation about NDA's prompted an interesting thought.

We have not heard anything about the progress of the SCOPE Trial ( SCIB1) for many months but we know the trial was progressing well because new clinical sites were opened.

Also, we were told at the AGM that the trial was in the process of being upgraded to iSCIB+. So could it be that SCIB1 is currently subject to discussions ( NDA's ) or maybe the whole Immunobody Platform which would mean the addition of Covidity ?

It would make complete sense of the lack of information regarding the SCOPE Trial especially with the recent Observer / Gaurdian article focusing on Lindy and Covidity..

Interesting.......🤔

Chester.

As always JB1 a well constructed assessment.

The fact that Scancell can't give us a blow by blow of the trial, it is really useful to have a structured timeline as you have set out.

We can all have a guess at the number of patients that have had their 1st dose by today's date but I'm happy to go with 50 or 60 patients.

So much happening in the background and now a very up front position in a well regarded Sunday and Daily newspaper.

We can also hope that both our GlyMab and AvidiMab technologies are in negotiations. Nearly half of 2023 has gone and Lindy did sound confident that deals would be done this year.

Thanks once again for the update JB1 👍

Chester.